Cataract Lens Options: Understanding Standard and Premium IOLs

Every cataract surgery involves the same fundamental step: your natural clouded lens is removed and replaced with an artificial intraocular lens (IOL). No lens removal, no cataract surgery — this is not optional. What is optional is the type of artificial lens that goes in. Understanding the differences between lens types — and the quality of evidence supporting each — puts you in a stronger position to have an informed conversation with your surgeon.

This guide organises IOL options into three broad tiers based on evidence maturity, cost, and clinical availability. It is designed to be educational, not promotional. The right lens for you depends on your individual eye health, lifestyle, and expectations — a decision made with your ophthalmologist, not before you walk in the door.

What Is an Intraocular Lens?

An intraocular lens is a small, flexible artificial lens — typically about 6 mm in diameter — implanted inside the eye after the cataract is removed. It sits in the same position as your natural lens, behind the iris and pupil, and provides the focusing power that your eye needs to see clearly. Modern IOLs are made from acrylic or silicone materials and are designed to last a lifetime. Unlike glasses or contact lenses, they require no maintenance and are not felt by the patient once the eye has healed.

The power of the IOL is calculated before surgery using precise biometric measurements of your eye. The goal is to reduce your dependence on glasses as much as possible — though whether you eliminate glasses entirely depends on the type of lens selected.

Tier 1 — Standard Monofocal IOL (MSP-Covered)

The standard monofocal lens corrects vision at a single focal distance, most commonly set to provide good distance vision (for driving, watching television, seeing faces). For near tasks — reading, phone use, fine detail work — reading glasses are typically still required. In some cases, the surgeon may target one eye for distance and one for near (a strategy called "monovision"), which can reduce glasses dependence without the additional cost of a premium lens.

Monofocal IOLs are the most thoroughly studied lens type in ophthalmology. Decades of randomised controlled trial data, registry data, and real-world outcomes support their safety and effectiveness. They are fully covered by BC's Medical Services Plan (MSP) when cataract surgery is medically indicated — there is no additional charge to the patient for the standard lens.

It is worth addressing a common misconception directly: choosing the MSP-covered monofocal lens is not choosing an inferior option. For patients whose primary goal is clear distance vision and who are comfortable wearing reading glasses, the standard monofocal lens offers outstanding results with the most comprehensive long-term evidence of any IOL. The premium upgrade discussion is about whether reducing glasses dependence further is worth the additional cost for your specific circumstances.

Tier 2 — Premium IOLs: Well-Evidenced Upgrades

Premium IOLs are lens options that carry an additional private cost above the MSP-covered base procedure. Three types have accumulated substantial peer-reviewed evidence and are offered by ophthalmologists with relevant expertise, including Dr. Sundaram.

Toric IOL — For Patients with Astigmatism

Astigmatism occurs when the cornea (the clear front surface of the eye) is not perfectly round — slightly more curved in one direction than the other. This causes blurred or distorted vision at all distances. A standard monofocal lens corrects for distance power but does not address astigmatism; patients with significant astigmatism would still need astigmatism-correcting glasses even after cataract surgery.

A toric IOL has an extra refractive component that corrects the astigmatism at the time of lens implantation. Careful pre-operative marking and alignment are required during the surgical procedure.

The evidence base for toric IOLs in cataract surgery is strong. Multiple randomised controlled trials demonstrate meaningful refractive benefits — patients with significant corneal astigmatism achieve substantially better uncorrected distance vision with toric IOLs compared to standard monofocals. A 2014 systematic review published in the Journal of Cataract and Refractive Surgery (de Vries et al.) found toric IOLs significantly outperformed standard lenses in reducing residual astigmatism and improving uncorrected visual acuity. This is Level I evidence supporting a real clinical benefit for the right patients.

Multifocal IOL — Reducing Glasses Dependence

Multifocal IOLs use diffractive or refractive optical zones to split incoming light into two or more focal points — typically one for distance and one for near — allowing patients to see at multiple distances without glasses. The goal is spectacle independence, and for well-selected patients, this goal is achievable.

The evidence base for multifocal IOLs has matured considerably over the past decade. A 2021 Cochrane systematic review (Cao et al., Cochrane Database of Systematic Reviews) found that patients receiving multifocal IOLs were significantly more likely to achieve spectacle independence compared to monofocal IOLs — a genuine and clinically meaningful benefit. However, the same review found that multifocal IOLs were associated with higher rates of dysphotopsias: halos, starbursts, and glare, particularly around lights at night. Many patients adapt over time through a process called neuroadaptation, but a minority find these symptoms persistently bothersome.

The practical conclusion from the evidence is that multifocal IOLs work well for carefully selected patients — those with realistic expectations, healthy corneas, no significant pre-existing ocular disease (such as macular degeneration or advanced glaucoma), and an active lifestyle where near vision without glasses is genuinely valued.

EDOF IOL — Extended Depth of Focus

Extended Depth of Focus (EDOF) lenses represent a middle path between monofocal and multifocal technology. Rather than splitting light into discrete focal points, EDOF lenses elongate the focal range, providing a continuous depth of useful vision — particularly for intermediate distances (computer work, dashboard reading, arm's-length tasks) — with fewer of the halos and glare associated with multifocal designs.

Clinical evidence for EDOF lenses is supportive. A review in the Journal of Cataract and Refractive Surgery examining outcomes with EDOF lens designs found that patients reported better intermediate vision and lower rates of dysphotopsias compared to multifocal IOLs, though near reading without glasses remained less consistent than with multifocal designs. Patients who primarily want good distance and intermediate vision — rather than the ability to read fine print without glasses — may find EDOF lenses a good fit.

As with all premium IOLs, patient selection remains the critical variable. EDOF lenses are not appropriate for patients with significant corneal irregularities, advanced macular disease, or unrealistic expectations about spectacle independence for all distances.

Tier 3 — Newer and Emerging Technologies

A third category of IOL technologies is available or in development, carrying either FDA approval for specific indications or Health Canada review status, but with a comparatively thinner evidence base than the well-established lens types above.

Light Adjustable Lens (LAL)

The Light Adjustable Lens (manufactured by RxSight) is a unique technology in which the IOL can be fine-tuned after implantation using a series of UV light treatments in the office. Once the desired refraction is achieved, the lens is "locked in" permanently. The potential advantage is refractive precision — the final power is adjusted based on actual post-operative healing, rather than calculated pre-operatively.

The LAL received FDA approval in the United States in 2017. Pivotal trial data (Hovanesian et al., 2020) showed improvements in uncorrected distance visual acuity compared to a standard IOL control — a positive outcome. However, the pivotal trial was sponsored by the manufacturer, and as of 2025, no independent Cochrane-level systematic review exists for this technology. Long-term (10+ year) outcome data remain limited compared to decades of monofocal and toric lens evidence. The lens also requires patient compliance: UV-protective glasses must be worn at all times between treatments until the lens is locked, and multiple follow-up office visits are needed.

This is not a critique of the technology — emerging evidence is generally positive for refractive precision in appropriate candidates, particularly patients with a history of prior LASIK or PRK where standard biometric calculations are less reliable. The point is that patients considering the LAL should understand the evidence maturity stage and have a clear conversation with their surgeon about whether the potential benefits justify the cost and compliance requirements for their specific situation.

Phakic IOLs (ICL — Implantable Collamer Lens)

Phakic IOLs — most commonly the Implantable Collamer Lens (ICL) — are a distinct category that deserves careful clarification: they are implanted in addition to the natural lens, not as a replacement. This means they are relevant only for patients who still have their natural lens intact — i.e., before cataracts develop — as a refractive correction alternative to LASIK or PRK for very high prescriptions.

Once a cataract has formed and surgery is required, the natural lens is removed entirely, and a phakic IOL is no longer appropriate. At that point, a standard cataract IOL is implanted instead. It is important to understand this distinction because the two technologies serve completely different patient populations.

For younger patients with very high myopia (short-sightedness) or hyperopia considering refractive surgery, ICL is a valid option. The Cochrane evidence base for phakic IOLs compared to laser refractive surgery is still limited — some studies suggest comparable or superior refractive outcomes for very high prescriptions, but long-term safety data versus established laser procedures continue to be studied.

A Note on Evidence Quality and Industry Funding

When evaluating clinical studies for any IOL, it is worth asking who funded the research. Research in the IOL field — as in many medical device fields — is frequently industry-sponsored, and there is well-documented evidence in the academic literature that industry-funded studies tend to report more favourable outcomes than independently funded research. This does not mean industry-funded studies are invalid, but it is a reason to place greater weight on independent systematic reviews, Cochrane analyses, and registry data when they are available. Researchers including Lundstrom and colleagues, writing in the Journal of Cataract and Refractive Surgery, have examined systematic biases in cataract surgical outcome reporting — this is a general principle of evidence appraisal, not an indictment of any specific technology.

Having an Informed Conversation with Your Surgeon

You do not need to arrive at your consultation with a decision already made about your IOL. What matters is arriving with good questions. A few useful starting points:

• What evidence base supports this lens? Ask specifically whether there are independent RCTs or Cochrane reviews, not just manufacturer data.
• What are the realistic tradeoffs? Every IOL involves tradeoffs — ask what you are trading away as well as what you stand to gain.
• Am I a good candidate based on my eye measurements? Premium lenses are not suitable for everyone — your corneal health and pre-existing ocular conditions matter.
• What does the MSP-covered lens offer me specifically? For many patients, the answer will be "excellent distance vision with reading glasses" — which may be perfectly acceptable.
• What would happen if I am unhappy with the result? IOL exchange is possible but involves a second surgical procedure and is not without risk.

A surgeon who welcomes these questions and takes time to answer them honestly — including being candid about the limitations of premium upgrades — is giving you the quality of consultation you deserve.